Exempt Offering Notice · D

BioLineRx Ltd.

Exempt Offering Notice

Filed Sep 9, 2026Accepted Sep 9, 2026, 4:30 PM EDTFiling CIK 1498403Accession 0001178913-26-004469

View company →Permanent SEC source ↗

Structured filing — D

primary_doc.xml

Open full document ↗

Issuer

Name: BioLineRx Ltd.
CIK: 0001498403
Entity type: Corporation
Jurisdiction: ISRAEL
Phone: 972-8-642-9100
Street: 2 HAMA'AYAN STREET
City: MODI'IN
State / country code: L3
State / country: ISRAEL
Postal code: 7177871
Incorporated more than five years ago: true
Previous issuer names: None
Previous EDGAR names: BioLineRX, Ltd.

Related person 1

First name: Philip
Middle name: A.
Last name: Serlin
Relationships: Executive Officer
Relationship clarification: Chief Executive Officer
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 2

First name: Mali
Last name: Zeevi
Relationships: Executive Officer
Relationship clarification: Chief Financial Officer
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 3

First name: Ella
Last name: Sorani
Relationships: Executive Officer
Relationship clarification: Chief Development Officer
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 4

First name: Aharon
Last name: Schwartz
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 5

First name: Rami
Last name: Dar
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 6

First name: BJ
Last name: Bormann
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 7

First name: Raphael
Last name: Hofstein
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 8

First name: Avraham
Last name: Molcho
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 9

First name: Sandra
Last name: Panem
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 10

First name: Shaoyu
Last name: Yan
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Related person 11

First name: Gal
Last name: Cohen
Relationships: Director
Street: BioLineRx Ltd.
Street (continued): 2 HaMa'ayan Street
City: Modi'in
State / country code: L3
State / country: ISRAEL
Postal code: 7177871

Offering

Industry: Biotechnology
Revenue range: Decline to Disclose
Exemption codes: 06b
Amendment: false
First sale date: 2026-08-27
Offering lasts more than one year: false
Option, warrant or other right to acquire a security: true
Business combination: false
Minimum investment accepted: 0
Total offering amount: 3,750,000
Amount sold: 3,750,000
Remaining amount: 0
Amount clarification: The securities were issued in connection with an offering of (i) 480,696 American depositary shares (ADSs) and 868,225 pre-funded warrants to purchase ADSs in a registered direct offering, and (ii) unregistered warrants to purchase 2,023,382 ADSs.
Non-accredited investors reported: false
Investors already participating: 1

Commissions, fees and proceeds

Sales commissions: 262,500
Finders’ fees: 0
Commission / fee clarification: Chardan is also entitled to 1.0% of the gross proceeds as management fee and $50,000 for accountable expenses.
Gross proceeds used: 0
Use of proceeds clarification: The Company intends to use the net proceeds or research and development activities and working capital and general corporate purposes.

Sales compensation recipient 1

Name: Chardan Capital Markets LLC
CRD: 000120128
Associated broker-dealer: None
Broker-dealer CRD: None
Foreign solicitation: false
Street: 1 Pennsylvania Plaza, Suite 4800
City: NEW YORK
State / country code: NY
State / country: NEW YORK
Postal code: 10119
States of solicitation: NY
Solicitation description: NEW YORK

Signature authorization

Authorized representative: false

Signature 1

Issuer: BioLineRx Ltd.
Signer: Mali Zeevi
Signed: /s/ Mali Zeevi
Title: Chief Financial Officer
Date: 2026-09-09

Company context

We are a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, focused on the advancement of GLIX1, a first-in-class, oral small-molecule therapy targeting the DNA damage response pathway in glioblastoma, or GBM, and other cancers. In September 2025, we entered into a collaboration transaction with Hemispherian AS, a Norwegian biotechnology company specializing in small-molecule cancer therapeutics, to develop, clinically evaluate, and commercialize GLIX1, Hemispherian’s lead drug candidate. Under the terms of the collaboration agreement, development of GLIX1 is being conducted by Tetragon Biosciences Ltd., a newly formed company and our subsidiary, established to advance the program.

Current securities

BLRXNASDAQ · ADR · Current

Historical securities (1)

BLNEFOTC · EQUITY · Historical · closed Mar 12, 2018

Get the free weekly BCS email.